A reprieve, not certainty

Recent U.S. pharmaceutical tariff measures focus primarily on patented and branded products, while generic medicines remain excluded at the time of writing. Since generics form the bulk of India’s pharmaceutical exports to the United States, the immediate impact on much of the sector is limited. The larger issue is not today’s exemption. It is the uncertainty around future policy, pricing pressure and reshoring incentives. A business that treats temporary relief as a permanent assumption is effectively outsourcing strategy to a policy decision it does not control.

Concentration is the underlying risk

For companies with material U.S. exposure, the relevant board question is not whether the market should be abandoned. It is whether the company has enough strategic options if margins, tariffs or buyer behaviour change.
Those options may include complex generics, specialty products, CDMO relationships, licensing structures,
selective U.S. manufacturing partnerships, or stronger channels in the UK, Europe, Africa, Latin America and
other regulated or semi-regulated markets.

API dependence belongs in the same conversation

Market concentration and input concentration are two sides of the same strategic risk. Indian pharmaceutical businesses continue to depend materially on imported APIs and intermediates. A company can diversify customers and remain exposed if its critical inputs still come from a narrow supply base. The appropriate response is rarely complete self-sufficiency. It is a deliberate map of critical dependencies, alternatives, inventory economics, domestic sourcing potential and partnership options.

QUESTIONS WORTH ASKING
• What percentage of revenue and profit depends on the U.S. market?
• Which products would remain attractive if tariff or pricing pressure increased materially?
• Could another geography replace even 15–20% of U.S.-linked revenue within 18 months?
• Which APIs or intermediates have no commercially realistic second source?

DANTAYA’S VIEW
Relief creates time. The best use of that time is not to predict policy; it is to create options. Diversification, partnerships and supply resilience take longer to build than most boards expect.